The Latest Breaking News on Pharma

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application. 

Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak fundamentals, the stock could be a poor choice for investors enticed by its negligible price. Let’s discuss….

Consumer goods giant Unilever is expanding its four-day work week trial to Australia after impressive results in New Zealand.

Rachel Carson, a scientist and writer from rural Pennsylvania, published Silent Spring 60 years ago. Many credit this book, which meticulously documented the damage that DDT pesticides were inflicting on wildlife, farm animals and people as early as the 1950s, with launching the modern environmental movement.

By Kevin Nicholson, COO of Delic and CEO of Ketamine Wellness Centers 

15 Global Psychedelics Executives To Keep An Eye On In 2022

This pandemic can help us prepare for the next one, says Catherine Hankins, co-chair of Canada’s COVID-19 Immunity Task Force

Indonesian authorities have revoked the licenses of two pharmaceutical companies to produce syrup-type medicines following the deaths of 159 children due to acute kidney injury

A surge in cases is indicating a new wave has started in the UK

Fainting and fatigue may signal onset of variant, experts say

Booster vaccinations are being offered to everyone in England over the age of 50